R&D | December 12, 2025
OTR Therapeutics and Zealand Pharma join forces to target metabolic diseases
The companies aim to expand treatment options for millions living with metabolic disorders
The companies aim to expand treatment options for millions living with metabolic disorders
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The study met its primary endpoint and all 11 secondary efficacy endpoints
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Subscribe To Our Newsletter & Stay Updated
